

Anand Vaidya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2545355/publications.pdf>

Version: 2024-02-01

93
papers

4,080
citations

117625

34
h-index

128289

60
g-index

93
all docs

93
docs citations

93
times ranked

4149
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. <i>Hypertension</i> , 2022, 79, 178-186.	2.7	29
2	Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients'™ Survival. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 964-971.	3.6	16
3	Discriminative Capacity of CT Volumetry to Identify Autonomous Cortisol Secretion in Incidental Adrenal Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1946-e1953.	3.6	1
4	Quality of Life and its Determinants in Patients With Adrenal Insufficiency: A Survey Study at 3 Centers in the United States. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2851-e2861.	3.6	5
5	Recalibrating Interpretations of Aldosterone Assays Across the Physiologic Range: Immunoassay and Liquid Chromatography-™ Tandem Mass Spectrometry Measurements Under Multiple Controlled Conditions. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac049.	0.2	12
6	Morphologically Normal-Appearing Adrenal Glands as a Prevalent Source of Aldosterone Production in Primary Aldosteronism. <i>American Journal of Hypertension</i> , 2022, 35, 561-571.	2.0	7
7	Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study. <i>Hypertension</i> , 2022, 79, 1984-1993.	2.7	17
8	Primary Aldosteronism: State-of-the-Art Review. <i>American Journal of Hypertension</i> , 2022, 35, 967-988.	2.0	26
9	Determinants of Self-reported Health Outcomes in Adrenal Insufficiency: A Multisite Survey Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1408-e1419.	3.6	19
10	Variability of Aldosterone Measurements During Adrenal Venous Sampling for Primary Aldosteronism. <i>American Journal of Hypertension</i> , 2021, 34, 34-45.	2.0	21
11	Intraindividual Variability of Aldosterone Concentrations in Primary Aldosteronism. <i>Hypertension</i> , 2021, 77, 891-899.	2.7	49
12	Assessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021, 35, 101491.	4.7	11
13	The Impact of the COVID-19 Pandemic on Self-Reported Outcomes in Patients With Adrenal Insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2469-e2479.	3.6	13
14	Quality of Life and Its Determinants in Patients With Adrenal Insufficiency: A Survey Study From Three Tertiary Centers in the United States. <i>Journal of the Endocrine Society</i> , 2021, 5, A92-A93.	0.2	0
15	Adrenocorticotrophic Hormone-™ Stimulated Adrenal Venous Sampling Underestimates Surgically Curable Primary Aldosteronism: A Retrospective Cohort Study and Review of Contemporary Studies. <i>Hypertension</i> , 2021, 78, 94-103.	2.7	19
16	American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach. <i>Endocrine Practice</i> , 2020, 26, 1366-1383.	2.1	25
17	The Unrecognized Prevalence of Primary Aldosteronism. <i>Annals of Internal Medicine</i> , 2020, 173, 10-20.	3.9	320
18	The Unrecognized Prevalence of Primary Aldosteronism. <i>Annals of Internal Medicine</i> , 2020, 173, 683.	3.9	5

#	ARTICLE	IF	CITATIONS
19	Evolution of the Primary Aldosteronism Syndrome: Updating the Approach. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3771-3783.	3.6	67
20	Dietary sodium intake and cortisol measurements. Clinical Endocrinology, 2020, 93, 539-545.	2.4	18
21	Disentangling the Relationships Between the Renin-Angiotensin-Aldosterone System, Calcium Physiology, and Risk for Kidney Stones. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1937-1946.	3.6	12
22	Primary aldosteronism. Gland Surgery, 2020, 9, 14-24.	1.1	3
23	MANAGEMENT OF ENDOCRINE DISEASE: The role of surgical adrenalectomy in primary aldosteronism. European Journal of Endocrinology, 2020, 183, R185-R196.	3.7	18
24	OR34-03 Variable and Pulsatile Circulating Aldosterone Levels in Primary Aldosteronism: Implications for Diagnosis and Sub-Type Differentiation. Journal of the Endocrine Society, 2020, 4, .	0.2	0
25	OR25-06 Morning ACTH Levels as a Reliable Biomarker for Excluding Autonomous Cortisol Secretion in Incidentally Discovered Adrenal Adenomas. A Prospective Cohort. Journal of the Endocrine Society, 2020, 4, .	0.2	0
26	MON-160 The Burdens of Adrenal Insufficiency: A Survey Study from Two Tertiary Care Centers in the United States. Journal of the Endocrine Society, 2020, 4, .	0.2	0
27	SAT-556 Use of ACTH-Stimulated Lateralization Indices Underestimates Surgically Curable Primary Aldosteronism. Journal of the Endocrine Society, 2020, 4, .	0.2	0
28	MON-164 Determinants of Quality of Life in Primary and Secondary Adrenal Insufficiency from Two Large Tertiary Care Centers in the United States. Journal of the Endocrine Society, 2020, 4, .	0.2	0
29	The prevalence of primary aldosteronism and evolving approaches for treatment. Current Opinion in Endocrine and Metabolic Research, 2019, 8, 30-39.	1.4	5
30	Primary adrenal insufficiency in the United States: diagnostic error and patient satisfaction with treatment. Diagnosis, 2019, 6, 343-350.	1.9	6
31	Primary Aldosteronism Diagnosis and Management. Endocrinology and Metabolism Clinics of North America, 2019, 48, 681-700.	3.2	22
32	The Evaluation of Incidentally Discovered Adrenal Masses. Endocrine Practice, 2019, 25, 178-192.	2.1	53
33	Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks. Hypertension, 2019, 73, 885-892.	2.7	121
34	Treatment of Adrenocortical Carcinoma. Surgical Pathology Clinics, 2019, 12, 997-1006.	1.7	40
35	Benign Adrenocortical Tumors and the Detection of Nonadrenal Neoplasia. International Journal of Endocrinology, 2019, 2019, 1-9.	1.5	0
36	Educational Note: Paradoxical collider effect in the analysis of non-communicable disease epidemiological data: a reproducible illustration and web application. International Journal of Epidemiology, 2019, 48, 640-653.	1.9	25

#	ARTICLE	IF	CITATIONS
37	Clinical, Biochemical, and Genetic Characteristics of "Nonclassic" Apparent Mineralocorticoid Excess Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 595-603.	3.6	26
38	Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study. <i>American Journal of Hypertension</i> , 2019, 32, 18-25.	2.0	15
39	SAT-388 The Influence of Dietary Sodium Intake on Cortisol and Glucose Homeostasis. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
40	OR04-1 Dietary Sodium Intake, the Renin-Angiotensin-Aldosterone System, and the Risk for Incident Kidney Stones. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
41	Response to Letter to the Editor: "Fibroblast Growth Factor 23, Mineral Metabolism, and Adiposity in Normal Kidney Function" <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 358-359.	3.6	0
42	EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease. <i>New England Journal of Medicine</i> , 2018, 378, 1259-1261.	27.0	41
43	A randomized intervention study to evaluate the effect of calcitriol therapy on the renin-angiotensin system in diabetes. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2018, 19, 147032031775417.	1.7	9
44	Prospective Study of Fasting Blood Glucose and Intracerebral Hemorrhagic Risk. <i>Stroke</i> , 2018, 49, 27-33.	2.0	40
45	Aging and Adrenal Aldosterone Production. <i>Hypertension</i> , 2018, 71, 218-223.	2.7	47
46	Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 51-59.	11.4	417
47	The Lateralizing Asymmetry of Adrenal Adenomas. <i>Journal of the Endocrine Society</i> , 2018, 2, 374-385.	0.2	21
48	The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment. <i>Endocrine Reviews</i> , 2018, 39, 1057-1088.	20.1	168
49	The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension. <i>Annals of Internal Medicine</i> , 2018, 168, 755.	3.9	2
50	The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor. <i>International Journal of Molecular Sciences</i> , 2018, 19, 546.	4.1	42
51	Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 658-666.	2.7	146
52	Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism. <i>JAMA Cardiology</i> , 2018, 3, 768.	6.1	148
53	Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus, Metabolic Syndrome and Related Disorders, 2017, 15, 269-275.	1.3	9
54	Body Size and the Risk of Primary Hyperparathyroidism in Women: A Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1900-1906.	2.8	10

#	ARTICLE	IF	CITATIONS
55	Plasma Glycated CD59, a Novel Biomarker for Detection of Pregnancy-Induced Glucose Intolerance. <i>Diabetes Care</i> , 2017, 40, 981-984.	8.6	35
56	Renin Phenotypes Characterize Vascular Disease, Autonomous Aldosteronism, and Mineralocorticoid Receptor Activity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1835-1843.	3.6	39
57	Genetic and Histopathologic Intertumor Heterogeneity in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1792-1796.	3.6	22
58	Age-Related Autonomous Aldosteronism. <i>Circulation</i> , 2017, 136, 347-355.	1.6	117
59	An Individualized Approach to The Evaluation and Management of Primary Aldosteronism. <i>Endocrine Practice</i> , 2017, 23, 680-689.	2.1	16
60	Continuum of Renin-Independent Aldosteronism in Normotension. <i>Hypertension</i> , 2017, 69, 950-956.	2.7	122
61	Resting Heart Rate Trajectory Pattern Predicts Arterial Stiffness in a Community-Based Chinese Cohort. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 359-364.	2.4	55
62	The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension. <i>Annals of Internal Medicine</i> , 2017, 167, 630.	3.9	127
63	Blood Pressure Trajectories and the Risk of Intracerebral Hemorrhage and Cerebral Infarction. <i>Hypertension</i> , 2017, 70, 508-514.	2.7	106
64	Adrenocortical carcinoma and succinate dehydrogenase gene mutations: an observational case series. <i>European Journal of Endocrinology</i> , 2017, 177, 439-444.	3.7	23
65	Fibroblast Growth Factor 23, Mineral Metabolism, and Adiposity in Normal Kidney Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1387-1395.	3.6	29
66	Angiotensin-Converting Enzyme Inhibition and Parathyroid Hormone Secretion. <i>International Journal of Endocrinology</i> , 2017, 2017, 1-8.	1.5	9
67	Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	41
68	Clinical Outcomes following Percutaneous Radiofrequency Ablation of Unilateral Aldosterone-Producing Adenoma: Comparison with Adrenalectomy. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 961-967.	0.5	33
69	Dietary Sodium Restriction Increases the Risk of Misinterpreting Mild Cases of Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3989-3996.	3.6	51
70	“Nonfunctional” Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes. <i>Annals of Internal Medicine</i> , 2016, 165, 533.	3.9	98
71	Parathyroid Hormone and the Use of Diuretics and Calcium-Channel Blockers: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1137-1145.	2.8	21
72	Response to Letter Regarding Article, “Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects”. <i>Circulation</i> , 2016, 133, e606.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Physical Activity and the Risk of Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1590-1597.	3.6	68
74	Cortisol dysregulation in obesity-related metabolic disorders. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 143-149.	2.3	40
75	Hypertension, Antihypertensive Medications, and Risk of Incident Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2396-2404.	3.6	22
76	Role of Complement and Complement Regulatory Proteins in the Complications of Diabetes. <i>Endocrine Reviews</i> , 2015, 36, 272-288.	20.1	127
77	Aldosterone, Parathyroid Hormone, and the Use of Renin-Angiotensin-Aldosterone System Inhibitors: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 490-499.	3.6	60
78	Genetics of Primary Aldosteronism. <i>Endocrine Practice</i> , 2015, 21, 400-405.	2.1	7
79	Succinate Dehydrogenase Gene Mutations in Cardiac Paragangliomas. <i>American Journal of Cardiology</i> , 2015, 115, 1753-1759.	1.6	30
80	Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. <i>Circulation</i> , 2015, 132, 1825-1833.	1.6	44
81	A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1674-1681.	3.4	31
82	Aldosterone Dysregulation With Aging Predicts Renal Vascular Function and Cardiovascular Risk. <i>Hypertension</i> , 2014, 63, 1205-1211.	2.7	42
83	Adrenocortical carcinoma: The management of metastatic disease. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 123-132.	4.4	43
84	Human Interventions to Characterize Novel Relationships Between the Renin-Angiotensin-Aldosterone System and Parathyroid Hormone. <i>Hypertension</i> , 2014, 63, 273-280.	2.7	69
85	Vitamin D and cardio-metabolic disease. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1697-1699.	3.4	13
86	Abnormal Aldosterone Physiology and Cardiometabolic Risk Factors. <i>Hypertension</i> , 2013, 61, 886-893.	2.7	47
87	Improving the Management of Diabetes in Hospitalized Patients: The Results of a Computer-Based House Staff Training Program. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 610-618.	4.4	16
88	The Independent Association Between 25-Hydroxyvitamin D and Adiponectin and Its Relation With BMI in Two Large Cohorts: The NHS and the HPFS. <i>Obesity</i> , 2012, 20, 186-191.	3.0	76
89	Vitamin D3 Therapy Corrects the Tissue Sensitivity to Angiotensin II Akin to the Action of a Converting Enzyme Inhibitor in Obese Hypertensives: An Interventional Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2456-2465.	3.6	59
90	Vitamin D and Vascular Disease: The Current and Future Status of Vitamin D Therapy in Hypertension and Kidney Disease. <i>Current Hypertension Reports</i> , 2012, 14, 111-119.	3.5	38

#	ARTICLE	IF	CITATIONS
91	The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 450-458.	3.4	124
92	The influence of body mass index and renin-angiotensin-aldosterone system activity on the relationship between 25-hydroxyvitamin D and adiponectin in Caucasian men. <i>European Journal of Endocrinology</i> , 2011, 164, 995-1002.	3.7	49
93	Lying Low. <i>New England Journal of Medicine</i> , 2011, 364, 871-875.	27.0	5